PDS Biotechnology Corp (PDSB) stock
PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.89−0.03 (-3.28%)
Close on Nov 17, 2026Market cap $50.03MP/E –Yield –
PDS Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
PDS Biotechnology's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.70M, down 26.5% year over year. For fiscal 2025 it was $19.03M, down 15.7% from the year before. Over ten years it grew 0.6% a year on average. The highest annual figure on record is $34.31M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.03M | -15.7% |
| FY2024 | Dec 31, 2024 | $22.57M | -18.7% |
| FY2023 | Dec 31, 2023 | $27.76M | -5.7% |
| FY2022 | Dec 31, 2022 | $29.43M | +161.5% |
| FY2021 | Dec 31, 2021 | $11.25M | +42.0% |
| FY2020 | Dec 31, 2020 | $7.92M | +29.9% |
| FY2019 | Dec 31, 2019 | $6.10M | +634.2% |
| FY2018 | Dec 31, 2018 | $830.74K | -97.6% |
| FY2017 | Dec 31, 2017 | $34.31M | +38.2% |
| FY2016 | Dec 31, 2016 | $24.83M | +39.2% |
| FY2015 | Dec 31, 2015 | $17.84M | +110.5% |
| FY2014 | Dec 31, 2014 | $8.47M | +89.0% |
| FY2013 | Dec 31, 2013 | $4.48M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.27M | -22.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.46M | -40.7% |
| Q4 FY2025 | Dec 31, 2025 | $4.41M | -2.7% |
| Q3 FY2025 | Sep 30, 2025 | $4.58M | -32.7% |
| Q2 FY2025 | Jun 30, 2025 | $4.21M | -7.0% |
| Q1 FY2025 | Mar 31, 2025 | $5.83M | -13.0% |
| Q4 FY2024 | Dec 31, 2024 | $4.53M | -39.3% |
| Q3 FY2024 | Sep 30, 2024 | $6.80M | +5.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.53M | -43.4% |
| Q1 FY2024 | Mar 31, 2024 | $6.70M | +14.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.47M | -53.8% |
| Q3 FY2023 | Sep 30, 2023 | $6.45M | +48.1% |
| Q2 FY2023 | Jun 30, 2023 | $8.00M | +112.8% |
| Q1 FY2023 | Mar 31, 2023 | $5.84M | +13.2% |
| Q4 FY2022 | Dec 31, 2022 | $16.16M | +376.7% |
| Q3 FY2022 | Sep 30, 2022 | $4.35M | +18.0% |
| Q2 FY2022 | Jun 30, 2022 | $3.76M | +36.1% |
| Q1 FY2022 | Mar 31, 2022 | $5.16M | +265.3% |
| Q4 FY2021 | Dec 31, 2021 | $3.39M | +36.8% |
| Q3 FY2021 | Sep 30, 2021 | $3.69M | +79.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.76M | +95.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.41M | -28.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.48M | +83.8% |
| Q3 FY2020 | Sep 30, 2020 | $2.06M | +12.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.41M | -25.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.97M | +91.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.35M | +405.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.83M | +845.2% |
| Q2 FY2019 | Jun 30, 2019 | $1.89M | +1019.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.03M | +412.1% |
| Q4 FY2018 | Dec 31, 2018 | $266.93K | -97.5% |
| Q3 FY2018 | Sep 30, 2018 | $194.07K | -97.2% |
| Q2 FY2018 | Jun 30, 2018 | $168.61K | -98.1% |
| Q1 FY2018 | Mar 31, 2018 | $201.14K | -97.3% |
| Q4 FY2017 | Dec 31, 2017 | $10.83M | +59.8% |
| Q3 FY2017 | Sep 30, 2017 | $6.91M | +2.8% |
| Q2 FY2017 | Jun 30, 2017 | $8.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.78M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.72M | – |
See a number that looks wrong?